Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05109_nanopub.RARUbr_v_0mbQ6HcUwu2paQIUxfdnPZUI--OLbs8uf5rE#assertion>. }
Showing items 1 to 15 of
15
with 100 items per page.
- drugbank:DB05109 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05109 label "Trabectedin [drugbank:DB05109]" assertion.
- drugbank:DB05109 seeAlso DB05109 assertion.
- drugbank:DB05109 identifier "drugbank:DB05109" assertion.
- drugbank:DB05109 description "Trabectedin, also referred as ET-743 during its development, is a marine derived antitumoral agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery.It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is also undergoing clinical trials for the treatment of breast, prostate, and paediatric sarcomas. The European Commission and the U.S. Food and Drug Administration (FDA) have granted orphan drug status to trabectedin for soft tissue sarcomas and ovarian cancer." assertion.
- drugbank:DB05109 title "Trabectedin" assertion.
- drugbank:DB05109 bio2rdf_vocabulary:identifier "DB05109" assertion.
- drugbank:DB05109 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05109 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05109" assertion.
- drugbank:DB05109 bio2rdf_vocabulary:x-identifiers.org DB05109 assertion.
- drugbank:DB05109 drugbank_vocabulary:drugbank-id "DB05109" assertion.
- drugbank:DB05109 drugbank_vocabulary:x-cas cas:114899-77-3 assertion.
- drugbank:DB05109 drugbank_vocabulary:x-atc atc:L01CX01 assertion.
- drugbank:DB05109 drugbank_vocabulary:x-pharmgkb pharmgkb:PA165958349 assertion.
- drugbank:DB05109 drugbank_vocabulary:x-wikipedia wikipedia:Trabectedin assertion.